TINAVI(SH:688277)2024-04-26 08:54Financial Performance - The company's operating revenue for Q1 2024 was ¥28,944,718.96, representing a decrease of 26.73% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥10,063,239.85, a decline of 216.49% year-over-year[5]. - The net cash flow from operating activities was -¥49,952,267.09, indicating a significant cash outflow[5]. - In Q1 2024, the company reported a net loss of CNY 10,063,239.85, compared to a net profit of CNY 3,728,197.47 in Q1 2023, representing a significant decline[21]. - The company’s total comprehensive income for Q1 2024 was CNY -10,049,093.81, down from CNY 3,624,921.95 in Q1 2023[22]. - The basic and diluted earnings per share for Q1 2024 were both CNY -0.02, compared to CNY 0.02 in Q1 2023[22]. Research and Development - Research and development expenses totaled ¥27,627,966.18, accounting for 95.45% of operating revenue, an increase of 29.51 percentage points from the previous year[6]. - The company’s development expenses increased to RMB 8,687,737.51 in Q1 2024, up from RMB 6,950,961.94 in Q1 2023, representing an increase of approximately 25%[17]. - Research and development expenses were CNY 25,891,190.61 in Q1 2024, slightly down from CNY 26,050,050.56 in Q1 2023[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,583,557,867.24, down 2.22% from the end of the previous year[6]. - The total assets as of March 31, 2024, were RMB 1,583,557,867.24, a decline from RMB 1,619,474,854.92 at the end of 2023[18]. - The total liabilities decreased to RMB 349,724,155.42 from RMB 381,951,829.60 at the end of 2023, indicating a reduction of approximately 8.4%[18]. - The company's long-term equity investments decreased to RMB 78,389,227.86 from RMB 93,289,065.43, reflecting a decline of about 15.9%[16]. - The company reported a net loss of RMB 477,279,887.14 in retained earnings as of March 31, 2024, compared to a loss of RMB 467,216,647.29 at the end of 2023[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,314[11]. - The top shareholder, Zhang Songgen, holds 75,664,000 shares, representing 16.84% of the total shares[11]. Cash Flow and Expenses - The company's cash and cash equivalents decreased to RMB 279,022,807.26 as of March 31, 2024, down from RMB 310,857,521.05 at the end of 2023[16]. - The company's operating cash flow for Q1 2024 was negative at CNY -49,952,267.09, an improvement from CNY -90,397,892.83 in Q1 2023[24]. - Cash and cash equivalents at the end of Q1 2024 were CNY 278,815,053.04, down from CNY 490,658,668.02 at the end of Q1 2023[25]. - The company incurred total sales expenses of CNY 22,132,576.97 in Q1 2024, a decrease from CNY 30,797,046.70 in Q1 2023, reflecting a reduction of approximately 28.3%[21]. Operational Metrics - The number of surgeries performed using the Tianji orthopedic surgical robot exceeded 8,000 in Q1 2024, marking an increase of over 80% year-on-year[13]. - As of the report date, the cumulative number of surgeries conducted with the Tianji orthopedic surgical robot surpassed 70,000[13]. - The total operating costs for Q1 2024 were RMB 79,862,623.61, down from RMB 94,531,368.13 in the same period last year, representing a reduction of about 15.6%[20]. - The company experienced a significant increase in the cash received from sales and services compared to the previous year, contributing to a reduction in operating expenses[9]. Investment Income - The company reported investment income of CNY 33,591,207.78 in Q1 2024, a decrease from CNY 48,548,114.13 in Q1 2023, indicating a decline of approximately 30.8%[21]. - Investment activities generated a net cash inflow of CNY 12,551,675.34 in Q1 2024, compared to CNY 13,417,405.60 in Q1 2023, showing a slight decrease[24].